Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03690986
Recruitment Status : Recruiting
First Posted : October 1, 2018
Last Update Posted : August 13, 2019
Sponsor:
Collaborator:
Vaccinex Inc.
Information provided by (Responsible Party):
Conor Steuer, Emory University

Brief Summary:
This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head and Neck Biological: VX15/2503 Biological: Ipilimumab Biological: Nivolumab Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

To evaluate the effect of VX15/2503 alone and VX15/2503 in combination with immune checkpoint inhibitors, ipilimumab or nivolumab, on the immune profile in the tumor microenvironment and in peripheral blood.

SECONDARY OBJECTIVE:

To extend the previously reported safety profile of single agent VX15/2503 to the combination of VX15/2503 and immune checkpoint inhibitors, ipilimumab or nivolumab, in patients with head and neck squamous cell carcinoma.

OUTLINE: Patients are randomized to 1 of 6 groups.

GROUP A: Patients receive VX15/2503 intravenously (IV) over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.

GROUP B: Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.

GROUP C: Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.

GROUP D: Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.

GROUP E: Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.

GROUP F: Patients undergo standard of care surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Actual Study Start Date : November 1, 2018
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A (VX15/2503)
Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
Biological: VX15/2503
Given IV
Other Names:
  • moAb VX15/2503
  • Anti-SEMA4D Monoclonal Antibody VX15/2503
  • Pepinemab

Experimental: Group B (VX15/2503, ipilimumab)
Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
Biological: VX15/2503
Given IV
Other Names:
  • moAb VX15/2503
  • Anti-SEMA4D Monoclonal Antibody VX15/2503
  • Pepinemab

Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Experimental: Group C (VX15/2503, nivolumab)
Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
Biological: VX15/2503
Given IV
Other Names:
  • moAb VX15/2503
  • Anti-SEMA4D Monoclonal Antibody VX15/2503
  • Pepinemab

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Experimental: Group D (nivolumab)
Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Experimental: Group E (ipilimumab)
Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

No Intervention: Group F (no treatment)
Patients undergo standard of care surgery.



Primary Outcome Measures :
  1. Change in immune profile in the tumor microenvironment [ Time Frame: Baseline up to 4-8 weeks after surgery ]
    Specimens from surgical resection will be collected under the guidance of the collaborating pathologist and tissue procurement staff at the time of surgery to capture tissue in excess of that needed for clinical staging and diagnostic purposes. Tumor specimens will be fixed in 10% formalin, embedded in paraffin and biomarkers related to activated HNSCC stroma will be assessed via immunohistochemical analysis.

  2. Change in circulating percentage of immune suppressor subsets in peripheral blood [ Time Frame: Baseline up to 4-8 weeks after surgery ]
    Blood samples will be collected and peripheral blood mononuclear cells will be isolated from these samples and stored in -80°C freezers until analysis. Multi-parameter flow cytometry will be utilized to phenotype immune effector cells. The impact of treatment on the circulating percentage of immune suppressor subsets that may serve as predictors of response to immune checkpoint inhibition. All data will be expressed as the percentage of total circulating peripheral blood cells with each respective phenotype.

  3. Phenotypic shifts in T lymphocyte subsets in peripheral blood [ Time Frame: Baseline up to 4-8 weeks after surgery ]
    Blood samples will be collected and peripheral blood mononuclear cells will be isolated from these samples and stored in -80°C freezers until analysis. Blood will be analyzed by multi-parameter flow cytometry to identify systemic phenotypic shifts mediated by VX15/2503 in combination with immune checkpoint inhibition.


Secondary Outcome Measures :
  1. Incidence of adverse events assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 4-8 weeks after surgery ]
    Adverse events will be classified using MedDRA System Organ Classes and Preferred Terms. Furthermore, serious adverse events, adverse events (AEs) with a severity grade of 3 or above using NCI CTCAE version 4.0, AEs deemed related to study drug, AEs leading to discontinuation of study drug, and AEs leading to death will also be summarized in preferred term by system organ class and listed on an individual subject basis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage I-IVA cytologically or histologically-proven head and neck squamous cell carcinoma (HNSCC), p16 positive and negative allowed
  • Oropharyngeal tumors must have p16 testing done
  • Cancer confirmed to be surgically resectable, with surgery evaluation with planned resection
  • Archival tissue prior to treatment available from at most 6 months prior to study enrollment. Otherwise new pre-treatment biopsy mandatory
  • No prior treatment for HNSCC
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Absolute neutrophil count ≥ 1,500 cells/µL
  • Platelets ≥ 100,000/µL
  • Hemoglobin ≥ 9.0g/dL (may receive packed red blood cell [prbc] transfusion)
  • Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
  • Albumin ≥ 3.0 g/dL
  • Serum creatinine ≤ 1.5 x ULN
  • Calculated creatinine clearance of ≤ 50 mL/min
  • International normalized ratio (INR) ≤ 1.5. Anticoagulation is allowed only with low molecular weight heparin (LMWH). Patient receiving LMW heparin on stable therapeutic dose for more than 2 weeks or with factor Xa level < 1.1 units/mL (U/mL) are allowed on the trial
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Ability to understand and willingness to sign a written informed consent document
  • Female subjects of childbearing potential must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and 3 months after completion
  • Male subjects must agree to use adequate contraception (e.g., condoms; abstinence) for the duration of study treatment and 3 months after completion
  • Female subjects of childbearing age must have a negative serum pregnancy test at study entry

Exclusion Criteria:

  • Poor venous access for study drug administration
  • Nasopharynx cancer, cancer of unknown primary, sinonasal cancer
  • Determined not to be a surgical candidate due to medical co-morbidities
  • Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)
  • Prior organ allograft or allogeneic bone marrow transplantation
  • Subjects with any active autoimmune disease or history of known or suspected autoimmune disease except for subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Women who are pregnant or lactating
  • Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study
  • Clinical evidence of bleeding diathesis or coagulopathy
  • Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate risk prostate cancer, or in situ carcinoma fully resected) unless disease free for a minimum of one year
  • Patients that have had prior treatment for HNSCC are not eligible
  • Active bacterial or fungal infections requiring systemic treatment within 7 days of treatment
  • Use of other investigational drugs (drugs not marked for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administration
  • History of severe hypersensitivity reactions to other monoclonal antibodies
  • Non-oncology vaccines within 28 days prior to or after any dose of ipilimumab
  • No archival tissue available pre-study treatment, and repeat biopsy not feasible

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690986


Contacts
Layout table for location contacts
Contact: Conor Steuer, MD 404-686-1753 csteuer@emory.edu
Contact: Nabil Saba, MD nfsaba@emory.edu

Locations
Layout table for location information
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Alexandra Hyduk    404-686-1753    alexandra.hyduk@emory.edu   
Contact: Derez Jones    404-686-3207    derez.jones@emory.edu   
Sponsors and Collaborators
Emory University
Vaccinex Inc.
Investigators
Layout table for investigator information
Principal Investigator: Conor Steuer, MD Emory University
Layout table for additonal information
Responsible Party: Conor Steuer, Principal Investigator, Emory University
ClinicalTrials.gov Identifier: NCT03690986    
Other Study ID Numbers: IRB00103534
NCI-2018-01263 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Winship4402-18 ( Other Identifier: Emory University Hospital/Winship Cancer Institute )
First Posted: October 1, 2018    Key Record Dates
Last Update Posted: August 13, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents